Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT04898543 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT04898543
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04898543 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 21, 2021
Completion date
May 31, 2026
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumor